Sign in

CIK 0001626971

  • Non-accelerated filer
  • Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464670809
Phone
+1 650-900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market buy President and CEO bought 15,008 shares at an average $3.00 ($45,029)
  2. 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
  3. 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
  4. 4 Open-market buy President and CEO bought 7,500 shares at an average $3.56 ($26,725)
  5. 4 Open-market sale 10% owner sold 1,492,956 shares at an average $4.07 ($6,077,845)
  6. 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
  7. 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market buy President and CEO bought 12,000 shares at an average $3.41 ($40,874)
  16. 4 Open-market buy President and CEO bought 15,212 shares at an average $3.49 ($53,039)
  17. 4 Open-market buy Chief Financial Officer bought 25,500 shares at an average $3.49 ($88,980)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 8 of 13 · 252 filings